[部分药物不当的商业推广及相关过高成本] - Suppr

Suppr

超能文献

[Inappropriate commercial presentation of selected drugs and associated overcost].

作者信息

Toledano Mayoral G, Salmerón García A, Román Márquez E, Cabeza Barrera J

出版信息

Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.

DOI:10.1016/s1130-6343(06)73972-1

PMID:16999568

Abstract

摘要

相似文献

[Inappropriate commercial presentation of selected drugs and associated overcost].

Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.

The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.

Eur J Haematol. 2010 Dec;85(6):484-91. doi: 10.1111/j.1600-0609.2010.01526.x.

Drug pricing: No cure, no cost.

BMJ. 2007 Jul 21;335(7611):122-3. doi: 10.1136/bmj.39267.432153.94.

Satisfaction guaranteed--"payment by results" for biologic agents.

N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.

Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S82-4. doi: 10.1016/j.jval.2011.05.013.

Bortezomib in multiple myeloma.

N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.

Bortezomib.

Nat Rev Drug Discov. 2003 Aug;2(8):611-2. doi: 10.1038/nrd1159.

Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.

Br J Haematol. 2010 Mar;148(5):810-2. doi: 10.1111/j.1365-2141.2009.07998.x. Epub 2009 Nov 16.

Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.

Manag Care Interface. 2004 Sep;17(9):52-61.

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.

Am J Health Syst Pharm. 2008 Jul 1;65(13):1221-31. doi: 10.2146/ajhp070272.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Inappropriate commercial presentation of selected drugs and associated overcost].

Farm Hosp. 2006 May-Jun;30(3):195-6. doi: 10.1016/s1130-6343(06)73972-1.

The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.

Eur J Haematol. 2010 Dec;85(6):484-91. doi: 10.1111/j.1600-0609.2010.01526.x.

Drug pricing: No cure, no cost.

BMJ. 2007 Jul 21;335(7611):122-3. doi: 10.1136/bmj.39267.432153.94.

Satisfaction guaranteed--"payment by results" for biologic agents.

N Engl J Med. 2007 Oct 18;357(16):1575-7. doi: 10.1056/NEJMp078204.

Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S82-4. doi: 10.1016/j.jval.2011.05.013.

Bortezomib in multiple myeloma.

N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.

Bortezomib.

Nat Rev Drug Discov. 2003 Aug;2(8):611-2. doi: 10.1038/nrd1159.

Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.

Br J Haematol. 2010 Mar;148(5):810-2. doi: 10.1111/j.1365-2141.2009.07998.x. Epub 2009 Nov 16.

Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.

Manag Care Interface. 2004 Sep;17(9):52-61.

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.

Am J Health Syst Pharm. 2008 Jul 1;65(13):1221-31. doi: 10.2146/ajhp070272.